Factors and timing of decreased adherence to S-1 in postoperative docetaxel + S-1 therapy for gastric cancer. Investigation of synergistic effects in trials of combination therapies with ...

2024年12月4日，北京大学肿瘤医院暨北京市肿瘤防治研究所、消化系肿瘤整合防治全国重点实验室、恶性肿瘤转化研究北京市重点实验室季加孚教授、沈琳教授团队在《自然通讯》（Nature Medicine）杂志上发表了题为“First-line ...

Disitamab vedotin already has a conditional approval in China for HER2-positive gastric cancer, and has been filed for HER2-positive bladder cancer on the strength of a pair of phase 2 trials.

Adding evorpacept to treatment with trastuzumab, ramucirumab, and paclitaxel may improve outcomes in HER2-positive gastric/GEJ cancer.

SOUTH SAN FRANCISCO - ALX Oncology Holdings Inc. (NASDAQ:ALXO), a clinical-stage biotechnology company with a market capitalization of approximately $95 million, reported positive outcomes from its ...

Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review updated data from trial evaluating CD47-blocker evorpacept in HER2-positive gastric cancer SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 ...

Predicting mortality in upper gastrointestinal tract cancer using long short-term memory neural networks. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

H.C. Wainwright analysts have reduced the price target for ALX Oncology (NASDAQ:ALXO) shares to $5 from the previous $25 ...

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on ALX Oncology Holdings (ALXO – Research Report). The ...